Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
This study is ongoing, but not recruiting participants.
Study NCT00183872 Information provided by USC/Norris Comprehensive Cancer Center
First Received on September 9, 2005. Last Updated on February 8, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gastric Cancer
Esophageal Neoplasms
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
Esophageal Diseases
Neoplasms
Stomach Neoplasms
More general conditions related to this trial
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Stomach Diseases
Interventions listed in this trial
irinotecan, docetaxel
Additional drug interventions recognized in this trial
Docetaxel
Irinotecan
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Sponsors listed in this trial
USC/Norris Comprehensive Cancer Center
Sanofi
Back to top of Main Content
